ArticlePloS one2025
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From HIV to SARS-CoV-2 associated neurological disorder ("HAND" to "SAND"): Viral infection as a "time-bomb" for the aging brain.Neuroscience applied · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) have been shown to have clinical benefits in treating high-risk patients with mild-moderate COVID-19. SARS-CoV-2 RNA in serum (RNAemia), is usually associated with severe disease and deaths. This study evaluates real-life data on the effectiveness of mAbs therapies against SARS-CoV-2 infections by different viral variants, particularly in the presence of RNAemia, focusing on clinical outcomes.
methodsFrom March 2021 to May 2022, high-risk patients with PCR-confirmed mild-moderate COVID-19 were enrolled at the Clinic of Infectious Diseases, San Paolo Hospital in Milan. Patients received Bamlanivimab/Bamlanivimab + Etesevimab/Casirivimab + Imdevimab/Sotrovimab based on Agenzia Italiana del Farmaco (AIFA) guidelines and prevalent SARS-CoV-2 variants. Nasopharyngeal swabs (NPS) and plasma samples were collected at infusion (t0) and after 7 days (t1). NPS viral loads and RNAemia were quantified using RT-qPCR, and variant typing was conducted. Clinical outcomes were evaluated, including time to symptom resolution and adverse effects.
resultsAmong 176 enrolled patients, treatment efficacy was observed in 96.6% with a median time to symptom resolution of 12 days (IQR 10-19). Viral load significantly decreased in both NPS and plasma by day 7 post-treatment (p<0.001). At t0, RNAemia was present in 61.9% of patients and NPS viral loads were higher in patients with RNAemia (p=0.002). However, after treatment, no significant differences in viral loads and times to symptom resolution were noted between patients with and without RNAemia. Omicron-infected patients exhibited higher plasma viral loads compared to Alpha and Delta variants (p<0.001) and the presence of RNAemia was significantly associated with Omicron (p<0.001). Vaccinated patients achieved faster recovery regardless of variant type (p=0.001).
conclusionEarly administration of anti-SARS-CoV-2 mAbs in high-risk patients significantly reduced viral loads in NPS and plasma and improved clinical outcomes. Despite the presence of RNAemia, these tailored mAb therapies led to favorable recovery times and minimal adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.